Athira Pharma Net Income
| ATHADelisted Stock | USD 4.74 0.10 2.16% |
As of the 5th of March, Athira Pharma shows the mean deviation of 4.12, and Risk Adjusted Performance of 0.0542. Athira Pharma technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
Athira Pharma's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Athira Pharma's valuation are provided below:Athira Pharma does not presently have any fundamental signals for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Athira |
Search Suggestions
| AT | Atlantic Power | CompanyDelisted |
| ATLCP | Atlanticus Holdings Corp | Company |
| ATI | Allegheny Technologies Incorporated | Company |
| ATACX | Atac Inflation Rotation | Mutual Fund |
| ATFV | Alger 35 ETF | ETF |
| ATXPRIME | ATX Prime | Index |
| ATP | ATP | Cryptocurrency |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
CompetitionBased on the recorded statements, Athira Pharma reported net income of (96.94 Million). This is 128.4% lower than that of the Biotechnology sector and 238.4% lower than that of the Health Care industry. The net income for all United States stocks is 116.98% higher than that of the company.
Athira Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Athira Pharma's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Athira Pharma could also be used in its relative valuation, which is a method of valuing Athira Pharma by comparing valuation metrics of similar companies.Athira Pharma is currently under evaluation in net income category among its peers.
Athira Fundamentals
| Return On Equity | -0.89 | |||
| Return On Asset | -0.42 | |||
| Current Valuation | 2.31 M | |||
| Shares Outstanding | 3.94 M | |||
| Shares Owned By Insiders | 13.36 % | |||
| Shares Owned By Institutions | 85.51 % | |||
| Number Of Shares Shorted | 7.03 K | |||
| Price To Book | 0.99 X | |||
| EBITDA | (95.81 M) | |||
| Net Income | (96.94 M) | |||
| Cash And Equivalents | 252.4 M | |||
| Cash Per Share | 6.67 X | |||
| Total Debt | 1.22 M | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 26.40 X | |||
| Book Value Per Share | 6.79 X | |||
| Cash Flow From Operations | (97.17 M) | |||
| Short Ratio | 0.37 X | |||
| Earnings Per Share | (9.67) X | |||
| Target Price | 4.0 | |||
| Number Of Employees | 26 | |||
| Beta | 2.8 | |||
| Market Capitalization | 26.62 M | |||
| Total Asset | 58.78 M | |||
| Retained Earnings | (406.15 M) | |||
| Working Capital | 41.71 M | |||
| Net Asset | 58.78 M |
About Athira Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Athira Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Athira Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Athira Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Other Consideration for investing in Athira Stock
If you are still planning to invest in Athira Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Athira Pharma's history and understand the potential risks before investing.
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |